Change background color
Change font size

Index of Department



  • Head of division
    Toru Motokura
We provide essential medicine for patients with blood diseases.

We provide high-quality treatment for all kinds of blood diseases focusing on patients. We aim to provide international-standard medicine not only for hematopoietic malignancy such as leukemia, malignant lymphoma, and multiple myeloma, but also autoimmune thrombocytopenia and aplastic anemia.

A scene of outpatient clinic

Field of expertise

We aim to provide the best treatment for hematopoietic malignancy such as leukemia, malignant lymphoma, and multiple myeloma by introducing therapeutic protocols, the efficacy of which has been demonstrated in international clinical studies and by consulting with patients and their families. We also provide treatment for autoimmune disorders such as aplastic anemia and autoimmune thrombocytopenia following the international guidelines. In particular, for malignant lymphoma and multiple myeloma, in collaboration with the Blood Transfusion Division, we try to improve the treatment results using super-high-dose chemotherapy with autologous peripheral blood stem cell transplantation. By collaborating with test departments, we often use genetic tests and flow cytometry tests for the diagnosis of hematopoietic malignancy and the monitoring of minimal residual disease.

Diseases of interests

  • Malignant lymphoma
  • Multiple myeloma
  • Acute leukemia
  • Myelodysplastic syndrome
  • Immunothrombocytopenia (idiopathic thrombocytopenic purpura )
  • Aplastic anemia

A scene of outpatient clinic

Principal treatment

  • Chemotherapy for hematopoietic malignancy
  • High-dose chemotherapy in combination with autograft for hematopoietic malignancy
  • Allogeneic hematopoietic stem cell transplantation from related donors for hematopoietic malignancy etc.
  • Immunosuppressive therapy for autoimmune hematologic disease

Principal tests

  • Bone marrow examination